Drug intelligence / Profile preview

Abilar Wound Balm

Development stage
Unknown
Lead developer
Repolar Pharmaceuticals
Administration
Topical
01

Overview

Abilar Wound Balm is a topical resin-based medical device developed by Repolar Pharmaceuticals for the treatment of infected and non-infected wounds. Its active ingredient is refined resin from Norway spruce (*Picea abies*), collected from Finnish Lapland and formulated at a 10% concentration in a petrolatum-based salve. The product works through multiple mechanisms: it creates a physical protective barrier against bacteria and yeasts that cause skin infections, provides intrinsic antimicrobial and anti-inflammatory effects, and promotes wound healing by maintaining an optimal moist wound environment. It is indicated for both acute and chronic wounds, including pressure ulcers, diabetic ulcers, leg ulcers, surgical wound complications, burns, lacerations, abrasions, and fissures. Abilar is classified as a CE-marked Class IIb medical device and is approved for both professional healthcare and home use.

Brand names
Abilar Wound BalmAbilar 10% Resin Salve
Other names
Abilar

Beyond the preview

Go deeper on Abilar Wound Balm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abilar Wound Balm.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call